Product Name:
PKCg-pS320
Product Number:
ab-pk972
Target Full Name: Protein-serine kinase C gamma
Target Alias: EC 2.7.11.13; Kinase PKC-gamma; KPCG; MGC57564; PKC I; PKCC; PKC-gamma; PKC-I; PRKCG; Protein kinase C, gamma; Protein kinase C, gamma type; SCA14
Product Type Specific: PKCg protein kinase phosphosite-specific antibody
Antibody Code: PK972
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: S320
Protein UniProt: P05129
Protein SigNET: PKCg
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Synthetic phosphopeptide patterned after human PKCg
Antibody Immunogen Sequence: RMGP(pS)SSPI(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues R316 to I324.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.4 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Rhesus Macaque | Rat.
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 75-85 kDa.
Related Product 1: CREB1 (123-135) KinSub kinase substrate peptide (Cat. No.: PE-01ACP95)
Related Product 2: PKCA/BSubtide kinase substrate peptide (Cat. No.: PE-01BIR95)
Related Product 3: PKCtide KinSub kinase substrate peptide (Cat. No.: PE-01ADL95)
Related Product 4: Syntide-2 KinSub kinase substrate peptide (Cat. No.: PE-01AQB95)
Related Product 5: PKCb S661 phosphorylation antibody (Cat. No.: AB-PK765)
Related Product 6: PKCb T500 phosphorylation antibody (Cat. No.: AB-PK766)
Related Product 7: PKC expression antibody (Cat. No.: AB-NK201)
Related Product 8: PKCa Y195 phosphorylation antibody (Cat. No.: AB-PK764)
Related Product 9: PKCa T497 phosphorylation antibody (Cat. No.: AB-PK763)
Related Product 10: PKCa T638 phosphorylation antibody (Cat. No.: AB-PK909)
Scientific Background: PKCg (Protein kinase C gamma type) is a calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that belongs to the protein kinase superfamily, AGC Ser/Thr protein kinase family, PKC subfamily. It plays diverse roles in neuronal cells and eye tissues, such as regulation of the neuronal receptors GRIA4/GLUR4 and GRIN1/NMDAR1, modulation of receptors and neuronal functions related to sensitivity to opiates, pain and alcohol, mediation of synaptic function and cell survival after ischemia, and inhibition of gap junction activity after oxidative stress. It phosphorylates GRIA4/GLUR4 glutamate receptor and regulates its function by increasing plasma membrane-associated GRIA4 expression. It functions in primary cerebellar neurons downstream of the metabotropic glutamate receptor GRM5/MGLUR5 and phosphorylates GRIN1/NMDAR1 receptor, which plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. PKCg is involved in the regulation of hippocampal long-term potentiation (LTP). It may be involved in desensitization of mu-type opioid receptor-mediated G protein activation in the spinal cord, and may be critical for the development and/or maintenance of morphine-induced reinforcing effects in the limbic forebrain. It modulates the functionality of mu-type-opioid receptors through phosphorylation and degradation of opioid receptors. It also contributes to chronic morphine-induced changes in nociceptive processing. It functions in neuropathic pain mechanisms and contributes to the maintenance of the allodynia pain produced by peripheral inflammation. PKCg plays an important role in initial sensitivity and tolerance to ethanol, by mediating the behavioral effects of ethanol as well as the effects of this drug on the GABA(A) receptors. During and after cerebral ischemia modulate neurotransmission and cell survival in synaptic membranes, and is involved in insulin-induced inhibition of necrosis, an important mechanism for minimizing ischemic injury. It is required for the elimination of multiple climbing fibers during innervation of Purkinje cells in developing cerebellum. It is activated in lens epithelial cells in response hydrogen peroxide treatment, and phosphorylates connexin-43 (GJA1/CX43), resulting in disassembly of GJA1 gap junction plaques and inhibition of gap junction activity which could provide a protective effect against oxidative stress. It phosphorylates p53/TP53 and promotes p53/TP53-dependent apoptosis in response to DNA damage. Involved in the phase resetting of the cerebral cortex circadian clock during temporally restricted feeding. It stabilizes the core clock component ARNTL/BMAL1 by interfering with its ubiquitination, thus suppressing its degradation, resulting in phase resetting of the cerebral cortex clock. It is characterized by its specific, restricted expression in the central nervous system (brain and spinal cord), particularly in the Purkinje cells of the cerebellum. Mutations in the PRKCG gene are associated with Spinocerebellar Ataxia type 14 (SCA14), a neurodegenerative disorder characterized by ataxia and cerebellar dysfunction. SCA14-associated mutations often cause the protein to form toxic amyloid-like aggregates, particularly when misfolded. This description may include information annotated by UniProt and/or Google AI.